A novel approach for identification of possible GSK-3β inhibitors using computational virtual screening analysis of drugs
by Kakarla Naga Madhavi Latha; G. Rama Mohan Babu
International Journal of Computational Biology and Drug Design (IJCBDD), Vol. 12, No. 4, 2019

Abstract: GSK-3 has a prominent role in glucose uptake and was investigated using more specific, ATP-competitive GSK-3 inhibitors. This multifunctional kinase apart from the ability to phosphorylate glycogen synthase and regulate glucose metabolism was subsequently found to be a critical component in numerous cellular functions including regulation of different cell signalling, cell division, differentiation, proliferation and growth as well as apoptosis. In this work, we report molecular docking analysis of 2035 approved drugs from DrugBank database based on their potential to bind against type-2 diabetes protein target, GSK-3β. Molecular docking analysis revealed several new classes of drugs reported to exhibit inhibitory properties against GSK-3β. Out of 13 best drugs resulted from the analysis, top three (Venetoclax, Cobicistat and Atorvastatin) were selected based on consensus scoring using six scoring schemes such as MolDock score of Molegro, mcule, Pose&Rank, MTiAutoDock, DockThor and DSX respectively.

Online publication date: Wed, 13-Nov-2019

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Computational Biology and Drug Design (IJCBDD):
Login with your Inderscience username and password:

Username:        Password:          Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com